Personalized medicine is partly based on biomarker-guided diagnostics, therapy and prognosis, which is becoming an unavoidable concept in modern cardiology. However, the clinical significance of single biomarker studies is rather limited. A promising novel approach involves combining multiple markers into a multiplex panel, which could refine the management of a particular patient with cardiovascular pathology. Two principally different assay formats have been developed to facilitate simultaneous quantification of multiple antigens: planar array assays and microbead assays. These approaches may help to better evaluate the complexity and dynamic nature of pathologic processes and offer substantial cost and sample savings compared with traditional enzyme-linked immunosorbent assay (ELISA) measurements. However, a multiplex multimarker approach cannot become a generally disseminated method until analytical problems are solved and further studies confirming improved clinical outcomes are accomplished. These drawbacks underlie the fact that a limited number of systematic studies are available regarding the use of a multiplex biomarker approach in cardiovascular medicine to date. Our perspective underscores the significant potential of the use of the multiplex approach in a wider conceptual framework under the close cooperation of clinical and experimental cardiologists, pathophysiologists and biochemists so that the personalized approach based on standardized multimarker testing may improve the management of various cardiovascular pathologies and become a ubiquitous partner of population-derived evidence-based medicine.

中文翻译：

---

多重生物标志物治疗心血管疾病的方法。

个性化医学部分基于生物标志物指导的诊断，治疗和预后，这已成为现代心脏病学中不可避免的概念。但是，单一生物标志物研究的临床意义相当有限。一种有前途的新方法涉及将多个标记物组合到一个多重面板中，这可以改善对特定心血管疾病患者的治疗。已经开发出两种主要不同的测定形式以促进多种抗原的同时定量：平面阵列测定和微珠测定。与传统的酶联免疫吸附测定（ELISA）测量相比，这些方法可能有助于更好地评估病理过程的复杂性和动态性质，并节省大量成本和样品。然而，除非解决了分析问题并且完成了进一步的研究以确认改善的临床结果，否则多重多重标记方法无法成为一种普遍使用的方法。这些缺点基于以下事实：迄今为止，关于在心血管医学中使用多重生物标志物方法的系统研究有限。我们的观点强调了在临床和实验心脏病学家，病理生理学家和生物化学家的密切合作下，在更广泛的概念框架中使用多重方法的巨大潜力，因此基于标准化多标记物检测的个性化方法可以改善对各种心血管疾病的管理，成为基于人群的循证医学的无处不在的合作伙伴。